Since resveratrol was reported to prevent liver fibrosis by inhibiting the Akt/NF-κB pathways [118], and COVID-19 causes prolonged fibrotic damage to the lung, a randomized clinical trial (NCT04799743) is currently recruiting to evaluate the anti-fibrotic therapeutic effects of resveratrol on discharged COVID-19 patients. This evidence concerns the gene AKT1 and COVID-19.